Loading...
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
BACKGROUND: The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell–receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3772525/ https://ncbi.nlm.nih.gov/pubmed/23782158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1215637 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|